Single-parent surrogacy involves three interconnected aspects: assisted reproduction, gestational carrying, and parental rights confirmation. The legal status and operational boundaries of single-parent surrogacy vary significantly across different countries and regions. This article examines the technical pathways, eligible individuals, procedural milestones, and common questions from medical and compliance perspectives.

I. Definition: What is “Single-Parent Surrogacy” and its Medical Implications?

From a medical standpoint, surrogacy is more accurately termed **“gestational carrier (GC)”**: a gestational carrier carries and delivers the pregnancy, typically with embryos created from intended parents (single individuals) and/or donor sperm/eggs, then transferred into the carrier's uterus. The American Society for Reproductive Medicine (ASRM) classifies GC arrangements as a category of assisted reproductive practices requiring rigorous screening, informed consent, and follow-up, emphasizing the importance of coordinated medical, psychological, and legal management.

Two distinct concepts require careful differentiation:

Gestational Surrogacy/Gestational Carriage: The carrier typically does not provide her own egg (more common).

Traditional surrogacy: The gestational carrier provides her own egg and carries the pregnancy (typically involves higher legal and ethical controversies, leading to greater caution in many jurisdictions).

Expert advice: Assessing the risks of “single-parent surrogacy” requires consideration beyond medical feasibility. Key factors include local legal permissibility, parental rights confirmation, and contract enforceability. Failure to address these may result in identity and custody complications despite medical success.

II. Technology: What are the core medical steps in single-parent surrogacy?

Technically, single-parent surrogacy combines “IVF/ICSI + embryo transfer to a gestational carrier (GC) + pregnancy management + postnatal parental rights confirmation.” Key medical stages include:

Fertility assessment and treatment plan selection

Female: AMH, basal follicles, hormones, uterine condition, etc.

Male: Semen analysis, genetic evaluations (if necessary).

Oocyte/Sperm Retrieval and Fertilization/Culture

Common methods include IVF or ICSI; embryo culture to blastocyst stage before transfer is more prevalent (though not universally optimal).

Whether to perform preimplantation genetic testing (PGT-A, etc.)

PGT-A screens embryos for chromosomal aneuploidy, potentially reducing risks of implantation failure/miscarriage in certain populations, but does not guarantee live birth. Regarding “add-ons,” the European Society of Human Reproduction and Embryology (ESHRE) emphasizes evidence-based use with clear indications, cautioning against presenting technologies as definitive guarantees.

GC (Gestational Carrier) Screening and Pregnancy Management

ASRM recommends systematic protocols for GC and intended parents, including infectious disease screening, psychological assessment, risk disclosure, and complication management.

Understanding Success Rates

In practice, success rates are influenced by age, embryo quality, uterine environment, and medical history. While the CDC publishes national ART summary data for understanding overall trends, individual outcomes vary significantly—overall statistics cannot replace personalized evaluations.

Expert Tip: Breaking down “success rate” into two layers offers greater control: Probability of obtaining viable embryos + Probability of pregnancy and live birth per single transfer. While single surrogacy typically delegates the second layer to the GC, the first layer remains dependent on gamete and embryo quality.

III. Population: Which singles consider this path? When is caution warranted?

Clinically, motivations for “single surrogacy” typically fall into three categories:

-   Absent/non-functional uterus: Congenital absence of uterus, severe uterine pathology, endometrial issues after repeated intrauterine procedures, etc.

-   High pregnancy risk rendering conception inadvisable: Severe cardiopulmonary disease, certain high-risk medical conditions, etc.

Family structure and reproductive planning factors: Individuals who are single but desire genetically related offspring (often requiring sperm/egg/embryo donation).

Situations requiring more careful evaluation:

Significant genetic disease risk without completed genetic counseling;

Poorly controlled severe chronic conditions (which may impact parenting capacity and long-term guardianship arrangements even if the individual does not carry the pregnancy);

Primarily relying on cross-border pathways with unclear destination country laws (heightened risks for subsequent parentage/nationality/birth certificate issues).

IV. Process: From Evaluation to Baby—Common Milestones and Potential Pitfalls

Below is a more operationally grounded milestone checklist (subject to regional adjustments based on legal and healthcare systems):

Stage    Key Actions    Common Bottlenecks/Risks

Compliance Pre-Assessment    Clarify destination laws, contract enforceability, parental rights pathways    Discrepancies in judicial interpretations; cross-border documents may not be recognized

Medical Assessment    Fertility testing, genetic counseling, infectious disease screening    Time investment; results impact treatment plans and budget

Embryo Stage Ovulation Induction/Sperm Retrieval, Fertilization & Culture, (Optional) PGT    Insufficient embryo yield; repeated egg retrieval

GC Stage    GC Screening, Transfer, Prenatal Care & Complication Management    Pregnancy complications; multiple pregnancy risk management

Birth & Parental Rights    Birth Certificate Documentation, Parental Rights Judgment/Adoption, etc.    Most prone to issues: identity, guardianship, border crossing

Compliance Reminder (China Context): In mainland China, regulatory authorities explicitly prohibit medical institutions and practitioners from performing any form of surrogacy technology.

This means: Pursuing surrogacy within China's domestic medical system is highly impractical and non-compliant, carrying significant legal and medical safety risks.

Overseas Variations (For illustrative purposes only; not legal advice):

Canada: Federal law does not prohibit surrogacy itself, but prohibits commercial surrogacy for “financial gain” and related payments/advertising, emphasizing altruistic intent and expense reimbursement boundaries.

United Kingdom: Commercial surrogacy and third-party advertising are restricted. Under UK law, the gestational carrier is typically recognized as the legal mother at birth, requiring court proceedings (e.g., parental order) to transfer legal parentage to the intended parents.

New York State, USA: The CPSA framework clarifies surrogacy agreements and parental rights procedures, explicitly permitting intended parents to be single adults (under specified conditions).

Expert Note: The most common pitfalls in single-parent surrogacy lie not in medicine but in documentation chains: how birth certificates are issued, how parental rights judgments are obtained, and whether return/entry materials are mutually recognized. Ensure a clear “legal roadmap” is established before proceeding with medical treatment.

V. Q&A: 6 High-Frequency Questions (Balanced Between Compliance and Medicine)

Q1: Does “technically feasible” mean “legally permissible” for single surrogacy?

No. Technical feasibility does not equate to legal viability. Contract validity, parental rights allocation, and fee classification vary significantly across countries/jurisdictions. UK guidance specifically emphasizes that parental rights transfer requires judicial processes.

Q2: Does using donor eggs/sperm complicate parentage?

Typically, it adds complexity to the “document chain”: clear donor rights relinquishment, parental rights adjudication conditions, and birth registration rules are required. New York CPSA documents explicitly outline parental rights procedures and participant requirements.

Q3: Does PGT-A provide greater certainty?

PGT-A may benefit certain groups but is not a “mandatory requirement.” ESHRE emphasizes evidence grading and indications for various assisted reproductive “add-ons,” cautioning against treating probabilistic tools as definitive outcomes.

Q4: Who bears the pregnancy risks for the GC?

Medical risks primarily affect the GC. Therefore, ASRM specifically emphasizes thorough informed consent, psychological support, medical autonomy, and complication management for the GC.

Q5: Are there “safer” regional options?

Some regions have clearer regulations, but “safety” depends on your individual circumstances: single status, nationality/residency requirements, cross-border procedures, egg/sperm donation, and methods of obtaining parental rights. For example, Canada has explicit restrictions on commercial payment.

Q6: If I'm in China, what should I do first?

Start with two steps:

Medical: Complete fertility assessment and genetic counseling to clarify medical reasons for surrogacy and alternative options.

Compliance: Understand destination laws and parental rights pathways—especially birth registration and repatriation documentation chains. Recognize China's regulatory red lines on surrogacy technologies. 

For fertility consultation in Kyrgyzstan, please contact your dedicated consultant

/Fertility Consultation /

Dr.Chan

Copy and add: Tulip_EnoChan

Or long press/scan the QR code to add

Tulip International Fertility Center

Technology aids fertility, fulfilling dreams for countless families